Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Operating Income (2021 - 2025)

Kezar Life Sciences' Operating Income history spans 5 years, with the latest figure at -$11.7 million for Q3 2025.

  • For Q3 2025, Operating Income rose 46.62% year-over-year to -$11.7 million; the TTM value through Sep 2025 reached -$65.5 million, up 36.79%, while the annual FY2024 figure was -$90.6 million, 18.68% up from the prior year.
  • Operating Income for Q3 2025 was -$11.7 million at Kezar Life Sciences, up from -$14.6 million in the prior quarter.
  • Across five years, Operating Income topped out at -$11.7 million in Q3 2025 and bottomed at -$34.6 million in Q4 2023.
  • The 5-year median for Operating Income is -$18.9 million (2022), against an average of -$19.6 million.
  • The largest annual shift saw Operating Income tumbled 72.65% in 2023 before it soared 46.62% in 2025.
  • A 5-year view of Operating Income shows it stood at -$14.1 million in 2021, then crashed by 42.05% to -$20.0 million in 2022, then crashed by 72.65% to -$34.6 million in 2023, then skyrocketed by 37.66% to -$21.6 million in 2024, then skyrocketed by 45.67% to -$11.7 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Operating Income are -$11.7 million (Q3 2025), -$14.6 million (Q2 2025), and -$17.6 million (Q1 2025).